108 related articles for article (PubMed ID: 25179684)
1. Natural compounds against neurodegenerative diseases: molecular characterization of the interaction of catechins from green tea with Aβ1-42, PrP106-126, and ataxin-3 oligomers.
Sironi E; Colombo L; Lompo A; Messa M; Bonanomi M; Regonesi ME; Salmona M; Airoldi C
Chemistry; 2014 Oct; 20(42):13793-800. PubMed ID: 25179684
[TBL] [Abstract][Full Text] [Related]
2. Effect of catechins and high-temperature-processed green tea extract on scavenging reactive oxygen species and preventing Aβ
Lee SB; Choi EH; Jeong KH; Kim KS; Shim SM; Kim GH
Nutr Neurosci; 2020 May; 23(5):363-373. PubMed ID: 30111271
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of Aβ aggregates in Alzheimer's disease by epigallocatechin and epicatechin-3-gallate from green tea.
Chen T; Yang Y; Zhu S; Lu Y; Zhu L; Wang Y; Wang X
Bioorg Chem; 2020 Dec; 105():104382. PubMed ID: 33137558
[TBL] [Abstract][Full Text] [Related]
4. How Epigallocatechin-3-gallate and Tetracycline Interact with the Josephin Domain of Ataxin-3 and Alter Its Aggregation Mode.
Bonanomi M; Visentin C; Natalello A; Spinelli M; Vanoni M; Airoldi C; Regonesi ME; Tortora P
Chemistry; 2015 Dec; 21(50):18383-93. PubMed ID: 26538519
[TBL] [Abstract][Full Text] [Related]
5. Flavonoids and Their Glycosides as Anti-amyloidogenic Compounds: Aβ1-42 Interaction Studies to Gain New Insights into Their Potential for Alzheimer's Disease Prevention and Therapy.
Guzzi C; Colombo L; Luigi A; Salmona M; Nicotra F; Airoldi C
Chem Asian J; 2017 Jan; 12(1):67-75. PubMed ID: 27766768
[TBL] [Abstract][Full Text] [Related]
6. Natural compounds against Alzheimer's disease: molecular recognition of Aβ1-42 peptide by Salvia sclareoides extract and its major component, rosmarinic acid, as investigated by NMR.
Airoldi C; Sironi E; Dias C; Marcelo F; Martins A; Rauter AP; Nicotra F; Jimenez-Barbero J
Chem Asian J; 2013 Mar; 8(3):596-602. PubMed ID: 23303581
[TBL] [Abstract][Full Text] [Related]
7. Neurodegeneration. Could they all be prion diseases?
Miller G
Science; 2009 Dec; 326(5958):1337-9. PubMed ID: 19965731
[No Abstract] [Full Text] [Related]
8. Towards a structural understanding of the fibrillization pathway in Machado-Joseph's disease: trapping early oligomers of non-expanded ataxin-3.
Gales L; Cortes L; Almeida C; Melo CV; Costa MC; Maciel P; Clarke DT; Damas AM; Macedo-Ribeiro S
J Mol Biol; 2005 Oct; 353(3):642-54. PubMed ID: 16194547
[TBL] [Abstract][Full Text] [Related]
9. Epigallocatechin-3-gallate and related phenol compounds redirect the amyloidogenic aggregation pathway of ataxin-3 towards non-toxic aggregates and prevent toxicity in neural cells and Caenorhabditis elegans animal model.
Visentin C; Pellistri F; Natalello A; Vertemara J; Bonanomi M; Gatta E; Penco A; Relini A; De Gioia L; Airoldi C; Regonesi ME; Tortora P
Hum Mol Genet; 2017 Sep; 26(17):3271-3284. PubMed ID: 28633380
[TBL] [Abstract][Full Text] [Related]
10. Understanding amyloid fibril nucleation and aβ oligomer/drug interactions from computer simulations.
Nguyen P; Derreumaux P
Acc Chem Res; 2014 Feb; 47(2):603-11. PubMed ID: 24368046
[TBL] [Abstract][Full Text] [Related]
11. Peptide aggregation in neurodegenerative disease.
Murphy RM
Annu Rev Biomed Eng; 2002; 4():155-74. PubMed ID: 12117755
[TBL] [Abstract][Full Text] [Related]
12. Mechanism of Nucleated Conformational Conversion of Aβ42.
Fu Z; Aucoin D; Davis J; Van Nostrand WE; Smith SO
Biochemistry; 2015 Jul; 54(27):4197-207. PubMed ID: 26069943
[TBL] [Abstract][Full Text] [Related]
13. Mode of substrate recognition by the Josephin domain of ataxin-3, which has an endo-type deubiquitinase activity.
Satoh T; Sumiyoshi A; Yagi-Utsumi M; Sakata E; Sasakawa H; Kurimoto E; Yamaguchi Y; Li W; Joazeiro CA; Hirokawa T; Kato K
FEBS Lett; 2014 Nov; 588(23):4422-30. PubMed ID: 25448680
[TBL] [Abstract][Full Text] [Related]
14. Destabilization of non-pathological variants of ataxin-3 by metal ions results in aggregation/fibrillogenesis.
Ricchelli F; Fusi P; Tortora P; Valtorta M; Riva M; Tognon G; Chieregato K; Bolognin S; Zatta P
Int J Biochem Cell Biol; 2007; 39(5):966-77. PubMed ID: 17300980
[TBL] [Abstract][Full Text] [Related]
15. Characterization of the structure and the amyloidogenic properties of the Josephin domain of the polyglutamine-containing protein ataxin-3.
Masino L; Nicastro G; Menon RP; Dal Piaz F; Calder L; Pastore A
J Mol Biol; 2004 Dec; 344(4):1021-35. PubMed ID: 15544810
[TBL] [Abstract][Full Text] [Related]
16. Epigallocatechin-3-gallate and tetracycline differently affect ataxin-3 fibrillogenesis and reduce toxicity in spinocerebellar ataxia type 3 model.
Bonanomi M; Natalello A; Visentin C; Pastori V; Penco A; Cornelli G; Colombo G; Malabarba MG; Doglia SM; Relini A; Regonesi ME; Tortora P
Hum Mol Genet; 2014 Dec; 23(24):6542-52. PubMed ID: 25030034
[TBL] [Abstract][Full Text] [Related]
17. Green tea and its polyphenolic catechins: medicinal uses in cancer and noncancer applications.
Zaveri NT
Life Sci; 2006 Mar; 78(18):2073-80. PubMed ID: 16445946
[TBL] [Abstract][Full Text] [Related]
18. Long-term green tea catechin administration prevents spatial learning and memory impairment in senescence-accelerated mouse prone-8 mice by decreasing Abeta1-42 oligomers and upregulating synaptic plasticity-related proteins in the hippocampus.
Li Q; Zhao HF; Zhang ZF; Liu ZG; Pei XR; Wang JB; Li Y
Neuroscience; 2009 Oct; 163(3):741-9. PubMed ID: 19596052
[TBL] [Abstract][Full Text] [Related]
19. Dietary polyphenol-derived protection against neurotoxic β-amyloid protein: from molecular to clinical.
Smid SD; Maag JL; Musgrave IF
Food Funct; 2012 Dec; 3(12):1242-50. PubMed ID: 22929970
[TBL] [Abstract][Full Text] [Related]
20. Polyglutamine diseases: the special case of ataxin-3 and Machado-Joseph disease.
Matos CA; de Macedo-Ribeiro S; Carvalho AL
Prog Neurobiol; 2011 Sep; 95(1):26-48. PubMed ID: 21740957
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
